Sahm Capital’s Chairman Shares Insights at Annual Financial Services Forum in Riyadh

RIYADH, SAUDI ARABIA – Media OutReach Newswire – 30 September 2024 – This past Saturday, the Annual Financial Services Forum in Riyadh successfully convened regulatory and industry leaders to discuss the future of the Saudi financial landscape. Hosted by j. awan & partners, the forum emphasized key strategies to enhance Saudi Arabia’s position as a global financial hub.

In attendance at the forum were key figures such as Mr. Raed Ibrahim Alhumaid, Deputy of Market Institutions at the Capital Market Authority (CMA), and Mr. Mohammed Al Rumaih, CEO of the Saudi Exchange, along with innovative entrepreneurs.

Steven Chou, Chairman of Sahm Capital, shared his insights on how Saudi Arabia can effectively compete with established financial powerhouses to attract top global talent. “Saudi Arabia has successfully drawn international professionals by offering diverse opportunities, and incentive policies,” Chou stated. “We have seen talent from financial hubs like Hong Kong relocate to the kingdom, enriching our financial ecosystem.”

Steven also discussed strategies such as relaxed visa policies and streamlined certificate recognition processes as essential incentives for attracting talent. He emphasized the growing importance of remote work structures and flexible arrangements in appealing to global professionals.

As the first non-bank international brokerage licensed by the CMA and the pioneer behind the innovative Sahm App, Sahm Capital has harnessed cutting-edge technology to serve domestic Saudi investors. This commitment has led Sahm Capital to become the fastest-growing brokerage in the KSA. Moreover, Sahm Capital has become the exclusive sponsor of the Saudi Tadawul Group’s Invest Wisely Program, aimed at improving financial literacy. Furthermore, the Sahm App has secured its position as one of the top three free finance apps in Saudi Arabia.

About Sahm Capital

Registered in Riyadh, Sahm Capital holds licenses (22251-25) from the Capital Market Authority (CMA) to conduct Dealing, Advising, and Custody services in KSA, making it the first non-bank international brokerage firm to provide online brokerage services in KSA. The company is also a registered member of the Saudi Exchange, as well as its affiliates, the Securities Depository Center Company (Edaa) and the Securities Clearing Center Company (Muqassa). For more information about Sahm, please visit: https://www.sahmcapital.com/

‫Montana Technologies تعلن عن عرض تقنية AirJoule® في معرض تكنولوجيا المياه والطاقة والبيئة (ويتيكس) في دبي بالتعاون TenX Investment

رونان، مونتريال , Oct. 02, 2024 (GLOBE NEWSWIRE) —  أعلنت اليوم شركة Montana Technologies Corporation، المدرجة في بورصة ناسداك تحت الرمز (AIRJ)، والمطورة لتقنية AirJoule® التحويلية لتوليد مياه الغلاف الجوي، عن تأسيس أول مكتب دولي لها في دولة الإمارات العربية المتحدة لتسريع نشر تقنية AirJoule® في المنطقة.

صرّح رئيس شركة Montana Technologies، السيد Ramdas Rao، قائلاً: “سيساعدنا إنشاء مكتب في الإمارات العربية المتحدة على تلبية الطلب المتزايد على قدرات تقنية AirJoule المتقدمة لإزالة الرطوبة وجمع مياه الغلاف الجوي من العملاء المحتملين في الأسواق سريعة النمو في الإمارات ودول مجلس التعاون الخليجي والهند. كما يُعزّز وجودنا في الإمارات جهودنا لتعزيز استراتيجياتنا العالمية في نشر هذه التقنية التحويلية.”

وأضاف السيد Rao: “تُعتبر كفاءة تقنية AirJoule في توفير الأمن المائي والتبريد المريح الموفر للطاقة هي الأهم في السوق، كما تتمتع التقنية بالقدرة على دعم إزالة الكربون بشكل مسؤول، مع المساهمة في التنمية السريعة ونمو البنية التحتية الحيوية في المنطقة. حكومة الإمارات سباقة للغاية في جذب ودعم التقنيات المتطورة التي تساعد في تحقيق التنمية المستدامة، ونتطلع إلى العمل عن كثب مع شركائنا المحليين والاستراتيجيين، واستخدام الإمارات كمركز رئيسي لتعزيز انتشارنا الدولي.”

من جهة أخرى، أعلنت شركة Montana Technologies عن توقيع مذكرة تفاهم مع TenX Investment in Energy Enterprises & Management Co. LLC، وهي شركة استثمارية متخصصة مقرها دبي تركز على دعم الاستثمارات في مجالات الطاقة والمياه. من خلال هذا التعاون الاستراتيجي، تهدف TenX Investment إلى توفير الدعم التقني و اللوجستي للمكتب الإقليمي الجديد لشركة Montana Technologies في دولة الإمارات، مما يساعد في تسريع نشر تقنية AirJoule® في المنطقة.

تُعد TenX Investment شريكاً أساسياً في نجاح افتتاح المكتب الإقليمي في الإمارات، حيث تعمل على تسهيل الشراكات مع الجهات الحكومية والمحلية ودعم الجهود التسويقية التي تهدف إلى توسيع نطاق استخدام تقنية AirJoule®يأتي هذا الدعم في إطار التزام TenX Investment بتعزيز الابتكار والاستدامة في قطاع الطاقة والمياه في الإمارات ودول مجلس التعاون الخليجي.

في هذا السياق، قال السيد Pat Eilers، الرئيس التنفيذي لشركة Montana Technologies: “تركز رؤية الإمارات 2030 بشكل كبير على الأمن المائي كأحد الجوانب الهامة في تحقيق أهداف التنمية المستدامة. ومن المتوقع أن تساهم قدرات تقنية AirJoule® في تعزيز الأمن المائي، ونحن متحمسون لتوسيع وجودنا في البلاد من خلال تأسيس مكتبنا الدولي، وبدعم من شريكنا الاستراتيجي TenX Investment، الذي يلعب دوراً محورياً في نجاح هذا المشروع.”

بالتزامن مع تأسيس مكتبها الدولي، ستعرض Montana Technologies تقنية AirJoule® في مؤتمر ويتيكس في دبي من 1 إلى 3 أكتوبر. يوفر معرض ويتيكس، الذي تنظمه هيئة كهرباء ومياه دبي، منصة لعرض التطورات التكنولوجية في مجالات الطاقة والمياه والموارد الطبيعية دعماً لرؤية دبي لبناء مستقبل مستدام. وتشجع الشركة الحضور في المعرض على زيارة جناحها (الجناح رقم F2-7) لمشاهدة عرض لوحدة AirJoule® لجمع المياه مباشرةً من الهواء والتخفيف من مشكلة ندرة المياه. بالإضافة إلى ذلك، يمكن دمج تقنية AirJoule® مع أنظمة التبريد بضغط البخار لتقليل استهلاك طاقة التكييف بنسبة تصل إلى 75%

Montana Technologies Corporation
Tom Divine – نائب الرئيس علاقات المستثمرين والتمويل
investors@mt.energ

GlobeNewswire Distribution ID 9250236

Novo Nordisk Gulf receives prestigious Best Places to Work Certification in Kuwait, Qatar, Bahrain, and Oman for 2024

KUWAIT CITY, KUWAIT – Media OutReach Newswire – 2 October 2024 – Novo Nordisk Gulf, a leading global healthcare company, has been recognized as one of the Best Places to Work for 2024 across Kuwait, Qatar, Bahrain, and Oman. This certification highlights the company’s dedication to fostering a supportive, innovative, and inclusive work environment for its employees while remaining committed to its mission of driving change to defeat serious chronic diseases.

During the certification process, Novo Nordisk Gulf received high ratings in key areas including employee engagement, leadership support, and workplace culture. These factors underscore the company’s success in creating a desirable workplace that aligns with its broader goal of improving health outcomes across the Gulf region.

Venkat Kalyan, Vice President & General Manager of Novo Nordisk Gulf Cluster, expressed his pride in the achievement: “We are honoured to receive the Best Place to Work recognition for Novo Nordisk Gulf Cluster. Our purpose is driving change to defeat serious chronic diseases, and this recognition serves as a testament of our commitment to this purpose, as well as our colleagues’ valuable efforts to build and sustain an innovative and inclusive workplace.”

Aydogan Cantimur, People & Organization Director at Novo Nordisk Gulf Cluster, also commented on the company’s achievement: “In Novo Nordisk Gulf Cluster, we are committed to ‘be the best workplace’ by continuously evolving our environment to the better and creating the best employee experience by implementing tangible and innovative HR practices. We are proud to be recognized as a Best Place to Work in Gulf Cluster again, which gives us the confidence that we are on the right track.”

 About Novo Nordisk

Novo Nordisk is a global healthcare company with over 95 years of innovation and leadership in diabetes care. Headquartered in Denmark, Novo Nordisk also leads in hemophilia care, growth hormone therapy, and hormone replacement therapy. The company employs approximately 70,000 people in 80 countries and markets its products in more than 170 countries.

For more information about Novo Nordisk and its commitment to the well-being of its employees and patients, visit www.novonordisk.com.

For more information, please visit www.bestplacestoworkfor.org.

LinkedIn: https://www.linkedin.com/company/best-places-to-work-program/

Twitter: http://www.twitter/bptw4

Duck Creek Technologies Launches Payments Facilitator to Create End-To-End Insurance Payment Solution

New Solution Simplifies Insurance Carriers’ Payments Delivering Secure Transaction Capabilities as Part of the Proven Duck Creek Platform

BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) — Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, today introduced its latest insurance-focused payments solution, the Duck Creek Payments Facilitator. This modern, end-to-end payment solution caters to the nuances of payments within insurance by providing carriers with access to digital payment methods for both collecting and disbursing funds.

Duck Creek Payments Facilitator delivers a global solution, combining real-time capabilities, like FedNow, with traditional payments services and Banking as a Service (BaaS) functionalities, such as transactions via push-to-card or digital wallets. Now insurers can collect or pay out to policyholders using any payment technologies in their market of choice.

“In today’s fast-evolving insurance landscape, carriers require more than just transactional solutions. They need a secure, agile, and future-proof approach to global payment processing,” said Jess Keeney, Chief Product and Technology Officer at Duck Creek Technologies. “The Duck Creek Payments Facilitator delivers exactly that—enabling insurers to effortlessly manage instant claims payouts to real-time premium payments—all from a single, proven solution.”

Duck Creek Payments includes Duck Creek Payments Facilitator and Duck Creek Payments Orchestrator, introduced earlier this year. The Duck Creek Payments Orchestrator is designed to seamlessly integrate with carriers existing systems, greatly reducing carrier integration times and costs, while still allowing access to the entire global payments ecosystem.

“As we continue to innovate and expand our offerings, our focus remains on solving the most critical challenges our insurance clients face,” said Michael Jackowski, Chief Executive Officer of Duck Creek Technologies. “The Duck Creek Payments Facilitator is designed specifically to address the unique operational demands of insurance carriers. By embedding this capability into our broader platform, we’re offering carriers a holistic approach that supports flexibility, boosts efficiency, and helps our clients deliver a frictionless experience for policyholders, agents, and vendors.”

For more information on the Duck Creek Payments Facilitator visit Duck Creek Payments.

About Duck Creek Technologies

Duck Creek Technologies is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry. We are the platform upon which modern insurance systems are built, enabling the industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations. Authenticity, purpose, and transparency are core to Duck Creek, and we believe insurance should be there for individuals and businesses when, where, and how they need it most. Our market-leading solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Visit www.duckcreek.com to learn more. Follow Duck Creek on our social channels for the latest information – LinkedIn and X.

Media Contacts:
Marianne Dempsey
duckcreek@threeringsinc.com

This press release was published by a CLEAR® Verified individual.

GlobeNewswire Distribution ID 9249862

Duck Creek Technologies Launches Payments Facilitator to Create End-To-End Insurance Payment Solution

New Solution Simplifies Insurance Carriers’ Payments Delivering Secure Transaction Capabilities as Part of the Proven Duck Creek Platform

BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) — Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, today introduced its latest insurance-focused payments solution, the Duck Creek Payments Facilitator. This modern, end-to-end payment solution caters to the nuances of payments within insurance by providing carriers with access to digital payment methods for both collecting and disbursing funds.

Duck Creek Payments Facilitator delivers a global solution, combining real-time capabilities, like FedNow, with traditional payments services and Banking as a Service (BaaS) functionalities, such as transactions via push-to-card or digital wallets. Now insurers can collect or pay out to policyholders using any payment technologies in their market of choice.

“In today’s fast-evolving insurance landscape, carriers require more than just transactional solutions. They need a secure, agile, and future-proof approach to global payment processing,” said Jess Keeney, Chief Product and Technology Officer at Duck Creek Technologies. “The Duck Creek Payments Facilitator delivers exactly that—enabling insurers to effortlessly manage instant claims payouts to real-time premium payments—all from a single, proven solution.”

Duck Creek Payments includes Duck Creek Payments Facilitator and Duck Creek Payments Orchestrator, introduced earlier this year. The Duck Creek Payments Orchestrator is designed to seamlessly integrate with carriers existing systems, greatly reducing carrier integration times and costs, while still allowing access to the entire global payments ecosystem.

“As we continue to innovate and expand our offerings, our focus remains on solving the most critical challenges our insurance clients face,” said Michael Jackowski, Chief Executive Officer of Duck Creek Technologies. “The Duck Creek Payments Facilitator is designed specifically to address the unique operational demands of insurance carriers. By embedding this capability into our broader platform, we’re offering carriers a holistic approach that supports flexibility, boosts efficiency, and helps our clients deliver a frictionless experience for policyholders, agents, and vendors.”

For more information on the Duck Creek Payments Facilitator visit Duck Creek Payments.

About Duck Creek Technologies

Duck Creek Technologies is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry. We are the platform upon which modern insurance systems are built, enabling the industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations. Authenticity, purpose, and transparency are core to Duck Creek, and we believe insurance should be there for individuals and businesses when, where, and how they need it most. Our market-leading solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Visit www.duckcreek.com to learn more. Follow Duck Creek on our social channels for the latest information – LinkedIn and X.

Media Contacts:
Marianne Dempsey
duckcreek@threeringsinc.com

This press release was published by a CLEAR® Verified individual.

GlobeNewswire Distribution ID 9249862

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

  • First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months
  • Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma

SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma.

Chris Gibson, Ph.D., Co-founder and CEO of Recursion said, “REC-1245 is a prime example of using an expansive AI-enabled platform for drug discovery. After exploring many predicted biological and chemical relationships across our maps of biology, we identified RMB39 as a novel target that looks functionally similar to the well-known but hard to drug target CDK12. We also identified and optimized small molecules that target RBM39 without directly impacting CDK12 or CDK13 using these same AI-enabled maps. In under 18 months, leveraging some of our newer chemistry tools, Recursion rapidly progressed REC-1245 from novel target biology to preclinical drug candidate, more than twice the speed of industry average.”

Recursion identified the novel regulatory role of RBM39 associated with CDK12 using its maps of biology and first reported this relationship in early 2023 at Download Day, Recursion’s R&D and investor event. Recursion believes the modulation of RBM39 may be associated with a therapeutic effect in certain biomarker-enriched solid tumors and lymphoma. Additionally, Recursion estimates that the initially addressable population for this potential therapeutic to be >100,000 patients in the US and EU5. REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile. Preclinical data support that RBM39 degradation induces splicing defects which downregulate DNA Damage Response (DDR) networks and cell cycle checkpoints.

“RBM39 degraders may offer a promising therapeutic approach for patients with solid tumors, particularly those with limited treatment options,” said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer at Recursion. “Recursion’s platform was among the first to rapidly uncover the therapeutic potential of RBM39 degradation, a finding now validated by independent research. This mechanism provides new opportunities for targeting tumors, which are often resistant to conventional treatments. By advancing this research, we aim to deliver a critical option for patients facing significant unmet needs, ultimately improving their prognosis and quality of life.”

The Phase 1/2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential monotherapy efficacy of REC-1245, and is expected to initiate in Q4 2024.

About Recursion

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements

This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the potential efficacy of REC-1245; timing of and plans to initiate dosing of Phase 1 clinical trial of REC-1245; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

GlobeNewswire Distribution ID 9249970